Search PubMed⌕ Search

PubMed · 3044329

Renal osteodystrophy.

Abstract

Over the past decade important advances in our understanding of the pathophysiology and treatment of renal osteodystrophy have been made. In particular, the role of calcitriol deficiency in the genesis of hyperparathyroidism in early renal failure is now better understood. So too are the effects of aluminium on bone, and whereas the more florid aluminium related disease is now unusual the more subtle effects of aluminium are now being appreciated. There is still a major problem in the long-term treatment of hyperparathyroid bone disease. The reasons why parathyroid gland proliferation continues to occur on dialysis therapy require a better understanding of cellular events regulating hormone production and parathyroid cell replication. The case for early intervention with vitamin D is now strong but whether such an approach materially influences the long-term outcome is not yet established. Changes in the approach to treatment and in the modalities used for renal replacement therapy will continue to modify the nature of the bone disease.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J A Kanis, T F Cundy, N A Hamdy. 1988. Renal osteodystrophy.. https://doi.org/10.1016/s0950-351x(88)80013-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Microbial stability evaluation of cement-based waste forms at different waste to cement ratio.

An evaluation of the effect of differences in chromium nitrate to cement ratio on the microbial stability of a chromium nitrate/cement waste form, as reflected in the leaching of chromium, calcium, magnesium and aluminum; was carried out in this study. An increase in the proportion of chromium in the waste form from 4.8 to 8.7% had no noticeable effect on microbial stability, with the total chromium leached essentially unchanged. Further increases in the proportion of chromium in the waste form from 8.7 to 10.7%, and from 10.7 to 15.9% resulted in a substantial decrease in microbial stability, with 3-fold and 1.3-fold increase in the total chromium leached, respectively, observed. For calcium, increases in the chromium proportion were accompanied with increases in the total calcium leached even though the increases were not in direct proportion to the increases in chromium proportion. For magnesium and aluminum, increases in the proportion of chromium within the range 4.8-10.7% were accompanied with increases in the total respective metals leached, with minor variation for each metal. On the whole, the maximum percentage chromium leached from the different waste forms was substantially lower than those of the other metals.

Aluminum↗

Aluminium and fluoride contents of tea, with emphasis on brick tea and their health implications.

Tea plant takes up a large quantity of aluminium (Al) and fluoride (F) from acidic soils. It has been known that fluorosis can be developed for people who consume a large quantity of tea made from brick tea, a low quality tea consisting mainly of old tea leaves in China. In addition, it has been claimed that Alzheimer's disease (AD) is linked with the Al content in the human brain. Therefore, the high Al content in tea, especially brick tea is also a concern. This article reviews the basis background on tea including classification, growth conditions, types of tea leaves and their production, and processing of tea. Special emphasis is made on the transfer of Al and F from soil to tea plant and then to tea liquor. Health implications of drinking a large quantity of tea liquor especially those made from brick tea are discussed. Recommendations are suggested to reduce the uptake of these two elements by tea plant, and lower their contents in tea products.

Aluminum↗

A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease.

Aluminum (Al(III)) and iron (Fe(III)) are reported to accumulate in neurofibrillary tangles of the Alzheimer's disease (AD) brain. In these lesions Al (III) and Fe (III) bind with hyperphosphorylated tau (PHFtau), the major constituent of the lesions, and induce its aggregation. It is thought that inhibition and dissociation of such Al (III)/Fe (III) binding associated with PHFtau could slow or halt the tau-related neurofibrillary degeneration in patients with AD. A study, using a previously developed in vitro system in which Al (III) and Fe (III) interact with PHFtau on AD brain sections and on immunoblot membranes showed that the potent Al (III)/Fe (III) chelator desferrioxamine elicited Al (III) chelation when subjected to autoclave heating. Here, the ability of a recently developed chemical chelator Feralex-G to remove PHFtau-bound Al (III)/Fe (III), using reaction conditions at 37 degrees C, was examined and compared with that of desferrioxamine. Chelation of Fe(III) was achieved by both compounds with no discernible difference in their chelating ability. In contrast, in the present system, the two chelators gave a different Al (III) chelation response. When incubated at 37 degrees C, desferrioxamine failed to attain notable Al (III) chelation, while Feralex-G displayed efficient Al (III) chelation. Thus, when considering competitive Al (III) removal from brain PHFtau, Feralex-G is a stronger chelator for Al(III) than desferrioxamine. The efficient Al (III) chelation attainable by Feralex-G adds weight to its potential clinical usefulness as a medicine in the aluminum/iron chelation therapy for patients with AD.

Aluminum↗